fasinumab

Home
Ligands
fasinumab

GtoPdb Ligand ID: 8965

Synonyms: REGN475 | SAR164877

Comment: Fasinumab is an investigational, fully human IgG4κ monoclonal antibody targeting nerve growth factor (NGF).
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record.
BLAST peptide sequence analysis reveals identical matches to peptide sequences submitted with patent US7988967 [4], with the preferred antibody being called REGN475 therein. REGN475 exhibits high specificity for human NGF, does not cross-react with closely related neurotrophin-3 (NT-3) and inhibits binding of NGF to its receptors TrkA (NTRK1) and p75 (NGFR) [4].

References
1. Hefti FF, Rosenthal A, Walicke PA, Wyatt S, Vergara G, Shelton DL, Davies AM. (2006) Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol Sci, 27 (2): 85-91. [PMID:16376998]
2. Hill R. (2011) Blocking the effects of NGF as a route to safe and effective pain relief--fact or fancy?. Pain, 152 (10): 2200-1. [PMID:21719197]
3. Leite VF, Buehler AM, El Abd O, Benyamin RM, Pimentel DC, Chen J, Hsing WT, Mazloomdoost D, Amadera JE. (2014) Anti-nerve growth factor in the treatment of low back pain and radiculopathy: a systematic review and a meta-analysis. Pain Physician, 17 (1): E45-60. [PMID:24452657]
4. MacDonald L, Torres R, Morra MR, Martin JH, Reinhardt JC. (2011) High affinity human antibodies to human nerve growth factor. Patent number: US7988967 B2. Assignee: Regeneron Pharmaceuticals, Inc.. Priority date: 10/08/2007. Publication date: 02/08/2011.
5. Tiseo PJ, Ren H, Mellis S. (2014) Fasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept study. J Pain Res, 7: 523-30. [PMID:25210473]

References

1. Hefti FF, Rosenthal A, Walicke PA, Wyatt S, Vergara G, Shelton DL, Davies AM. (2006)
Novel class of pain drugs based on antagonism of NGF.
Trends Pharmacol Sci, 27 (2): 85-91. [PMID:16376998]

2. Hill R. (2011)
Blocking the effects of NGF as a route to safe and effective pain relief--fact or fancy?.
Pain, 152 (10): 2200-1. [PMID:21719197]

3. Leite VF, Buehler AM, El Abd O, Benyamin RM, Pimentel DC, Chen J, Hsing WT, Mazloomdoost D, Amadera JE. (2014)
Anti-nerve growth factor in the treatment of low back pain and radiculopathy: a systematic review and a meta-analysis.
Pain Physician, 17 (1): E45-60. [PMID:24452657]

4. MacDonald L, Torres R, Morra MR, Martin JH, Reinhardt JC. (2011)
High affinity human antibodies to human nerve growth factor.
Patent number: US7988967 B2. Assignee: Regeneron Pharmaceuticals, Inc.. Priority date: 10/08/2007. Publication date: 02/08/2011.

5. Tiseo PJ, Ren H, Mellis S. (2014)
Fasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept study.
J Pain Res, 7: 523-30. [PMID:25210473]